Clinical Trial Update: 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update assesses 24-hour lung function in adults with moderate to very severe COPD after treatment with PT003 compared with placebo M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT003
• Placebo MDI

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2017-04-19